FULL PUBLISHED RESEARCHEarnings and management commentary analysis
Sage PRO · GICHSGFIN · Quarter ended 30 September 2026 · 18 November 2026
Stance: Watch. The earnings rebound needs a cleaner credit bridge before the discount to book can be interpreted as a durable recovery.
1. Investment decision
Key takeaways
- Standalone quarterly PAT reached ₹57.19 crore, up 14.5% from ₹49.95 crore and sharply above ₹10.04 crore in June.
- Revenue from operations grew only 1.5% year on year.
- The gap between revenue and PAT growth puts the burden of proof on provisioning and collections, rather than on balance-sheet growth.
Standalone PAT (₹ crore)
Standalone PBT (₹ crore)
2. Financial quality
Key takeaways
- Standalone PBT rose from ₹17.69 crore in June to ₹71.64 crore in September.
- Impairment swung from an expense of ₹32.49 crore to a reversal of ₹17.11 crore, a ₹49.60 crore tailwind against a ₹53.95 crore PBT increase.
- Adding the signed impairment expense back to reported PBT gives ₹54.53 crore in September versus ₹50.18 crore in June and ₹59.36 crore a year earlier.
This simple pre-impairment bridge still includes all other items and shows weaker underlying profit year on year.
Signed impairment expense (₹ crore)
Pre-impairment PBT, calculated (₹ crore)
3. Business and origination
Key takeaways
- H1 sanctions fell from ₹1,134 crore to ₹973 crore and disbursements from ₹1,023 crore to ₹939 crore, while September gross loans rose 4% to ₹11,261 crore.
- A larger closing book can coexist with weaker current origination.
- Track sanctions-to-disbursements and repayments separately before extrapolating loan growth.
Operating revenue (₹ crore)
Gross loan portfolio (₹ crore)
4. Credit risk
Key takeaways
- Gross NPA balances increased from ₹491 crore to ₹514 crore and net NPA from ₹211 crore to ₹238 crore.
- Gross NPA rose from 4.52% to 4.57% and net NPA from 1.99% to 2.16%.
- A quarterly impairment reversal alongside higher year-on-year NPA stocks merits a roll-forward separating recoveries, new slippages, write-offs and model changes.
Gross NPA balance (₹ crore)
Net NPA balance (₹ crore)
5. Funding and capital
Key takeaways
- H1 cost of borrowed funds fell 33 bps while yield on advances fell 38 bps and NIM fell 6 bps.
- Funding relief alone did not lift margin.
- Reported leverage fell to 4.24 times from 4.50 times.
Staff and other expenses also increased, making new origination productivity important to recovery economics.
H1 disbursements (₹ crore)
H1 NIM (%)
6. Peers and valuation
Key takeaways
- Use Repco and LIC Housing as operating references for collections and cost of risk.
- Repco reduced gross NPA balances year on year, whereas GIC’s gross and net balances increased.
- GIC’s reported H1 return on net worth is a half-year measure.
Comparing it directly with an annualized quarterly peer ROE would overstate the return gap.
The 17 November market reference was ₹133.19. Against disclosed book value of ₹399.22 per share, that is about 0.33 times reported book. How much tangible equity remains after a through-cycle credit adjustment drives the interpretation of that discount.
7. Scenarios and monitoring
Key takeaways
- A sustained recovery needs cash collections and lower net NPA balances alongside stable pre-impairment earnings.
- The bear case is a renewed positive credit charge against weak new originations.
- A stronger case would combine lower absolute problem loans and a recovery in sanctions without another decline in asset yields.
Sensitivity. An annualized 25 basis point change applied to the reported closing gross loan portfolio is equivalent to approximately ₹28.2 crore before tax. This isolates scale. Realized effects depend on average on-balance-sheet assets, assigned balances, repricing, funding and the timing of income or provisions.
Additional institutional diligence — what the impairment reversal really means
Key takeaways
- The central distinction in GIC Housing Finance's September quarter is the difference between reported profit and profit before impairment movements.
- On the signed standalone series already quoted above, Q2 FY27 PBT was ₹71.64 crore versus ₹61.15 crore a year earlier, approximately 17% higher.
- However, adding back the *signed* impairment expense produces pre-impairment PBT of ₹54.53 crore versus ₹59.36 crore, approximately 8% lower year on year.
That is a materially different picture: much of the apparent profit acceleration is credit-cost timing rather than evidence of a stronger underlying spread or operating engine. This arithmetic is an analyst reconstruction from the NSE-filed standalone results, not the issuer's separate pre-provision operating-profit label.
Sequentially, the ₹49.60 crore swing from a ₹32.49 crore charge in June to a ₹17.11 crore reversal in September explains roughly 92% of the ₹53.95 crore PBT improvement. The comparison is striking, but it should not be used to assert that the reversal was inappropriate.
Recoveries, provision coverage and model changes can legitimately move the charge. The next earnings call must provide an actual NPA roll-forward, including additions, cures, technical write-offs, recoveries and classification changes, to determine how much of the reversal can be recurring.
A superficially strong reported PAT should not be annualized without that bridge.
Collections versus origination: The closing gross loan book increased from ₹10,870 crore to ₹11,261 crore, roughly 3.6%, while H1 disbursements fell from ₹1,023 crore to ₹939 crore, around 8%. These are different measurement periods, and a growing closing book does not contradict slower disbursements.
But weaker new business can become a drag on subsequent interest income even while the quarter benefits from a credit reversal. Gross NPA balances actually rose from ₹491 crore to ₹514 crore and net NPA from ₹211 crore to ₹238 crore.
The simultaneous rise in problem-loan *stocks* and reversal of provision expense is the most valuable question to pursue with management.
Economics and valuation discipline: The H1 net interest margin moved from 3.32% to 3.26%, despite a fall in cost of borrowing, because asset yields also fell. A discount to disclosed book value is not by itself a catalyst: book value can change through credit losses or slow capital deployment, and a 17 November market quote does not provide a repeatable current valuation.
The appropriate next step is a cross-period reconciliation of tangible book, expected losses, average yielding assets and normalized post-provision return on equity. Until supplied, the stance remains WATCH.
Operational monitoring tests: Ask for (1) sanctions and actual disbursements for the next quarter, not just the closing loan stock; (2) cash-based NPA recoveries and fresh slippages; (3) the impairment roll-forward explaining the reversal; (4) asset yield versus weighted borrowing cost; and (5) incremental earnings before credit costs. A durable bull case needs improving loan quality *and* new-business momentum.
The bearish disconfirmation is another high reported PAT quarter driven predominantly by provision reversal while originations and pre-impairment PBT remain weak. These are analyst tests, not issuer promises or forecasts.
The numerical inputs are from the NSE September 2026 financial results and highlights already identified in the evidence ledger below.
Evidence and limitations
Key takeaways
- The analysis uses results and disclosures for the September 2026 quarter.
- Ratios and financial balances use the issuer’s definitions.
- Figures rounded by the issuer can produce small differences when percentage changes are recalculated.
Scenario assumptions represent operating outcomes. Comparable diluted peer valuation, granular maturity buckets and loan-cohort performance remain diligence items. Market price is an observation from 17 November.
-